

AMENDMENT

In the Claims:

Please amend the claims as follows:

Please cancel claims 2-5 and 32-71 without prejudice or disclaimer.

Please add the following new claims:

72. (New) A method for modulating the status of cancer cells that express 20P1F12/TMPRSS2, the method comprising:
administering to the cancer cells an antibody or fragment thereof that specifically binds to a 20P1F12/TMPRSS2-related protein, whereby the status of a cell that expresses 20P1F12/TMPRSS2 is modulated.

73. (New) The method of claim 72, wherein said antibody or fragment is a monoclonal antibody, or fragment thereof.

74. (New) The method of claim 72, wherein said antibody or fragment is a recombinant protein comprising the antigen-binding region of an antibody that specifically binds to a 20P1F12/TMPRSS2-related protein.

75. (New) The method of claim 72, wherein said antibody or fragment is labeled with a detectable marker.

76. (New) The method of claim 72, wherein said antibody or fragment is conjugated with a cytotoxic agent.

77. (New) The method of claim 72, wherein said antibody or fragment is a human antibody or fragment.

78. (New) The method of claim 72, wherein said antibody or fragment is administered by administering a recombinant polynucleotide that encodes the antibody or fragment thereof.

79. (New) The method of claim 72 wherein the cancer cells are in a mammal.

80. (New) The method of claim 79, wherein the mammal is a human and the said antibody or fragment is a recombinant protein which comprises a chimeric or humanized antibody.

81. (New) The method of claim 80, wherein said antibody or fragment is administered with a pharmaceutically acceptable carrier.

82. (New) The method of claim 80, said antibody or fragment is administered as the composition in a human patient dose.

83. (New) The method of claim 72 wherein modulating the status of cancer cells comprises inhibiting growth of the cancer cells.

84. (New) The method of claim 72 wherein modulating the status of cancer cells comprises inhibiting survival or viability of the cancer cells.